Chinook Therapeutics and Evotec joined forces for a patient-centric target identification supported by strong translational evidence to initiate drug discovery programs with a focus on tubular failed repair and cross-talk in the tubulointerstitial niche.
1 Evotec SE and
2 Chinook Therapeutics Inc
